Form 8-K - Current report:
SEC Accession No. 0001104659-23-023768
Filing Date
2023-02-21
Accepted
2023-02-21 16:01:30
Documents
14
Period of Report
2023-02-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm237425d1_8k.htm   iXBRL 8-K 31191
2 EXHIBIT 99.1 tm237425d1_ex99-1.htm EX-99.1 10379
6 GRAPHIC tm237425d1_ex99-1img001.jpg GRAPHIC 6063
  Complete submission text file 0001104659-23-023768.txt   229207

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cldx-20230216.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20230216_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20230216_pre.xml EX-101.PRE 22617
8 EXTRACTED XBRL INSTANCE DOCUMENT tm237425d1_8k_htm.xml XML 3522
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 23647986
SIC: 2835 In Vitro & In Vivo Diagnostic Substances